P
DWTX

&Partners’s Dogwood Therapeutics DWTX Stock Holding History

&Partners’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-440
Closed -$1.87K – 1683
2024
Q3 		$1.87K Hold
440
– – ﹤0.01% 1390
2024
Q2 		$2.37K Hold
440
– – ﹤0.01% 914
2024
Q1 		$5.27K Hold
440
– – ﹤0.01% 491
2023
Q4 		$6.33K Hold
440
– – ﹤0.01% 294
2023
Q3 		$10.2K Hold
440
– – ﹤0.01% 183
2023
Q2 		$15.2K Hold
440
– – 0.01% 195
2023
Q1 		$4.04K Hold
440
– – ﹤0.01% 182
2022
Q4 		$2.6K Hold
440
– – ﹤0.01% 187
2022
Q3 		$4K Hold
440
– – ﹤0.01% 185
2022
Q2 		$47K Buy
+440
New +$46K 0.03% 189

Other funds holding DWTX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

&Partners's DWTX Position: Q4 2024 in Review

&Partners sold out of Dogwood Therapeutics (DWTX) in Q4 2024, closing a stake of 440 shares — an estimated $1.87K sold.

&Partners first reported a position in DWTX in Q2 2022 and held it in 10 quarters. The position peaked at $47K in Q2 2022. 10 funds tracked by Wall St. Rank hold DWTX as of Q4 2024.

  • &Partners reported no remaining Dogwood Therapeutics position as of Q4 2024 after selling out during the quarter.
  • &Partners sold 440 Dogwood Therapeutics shares in Q4 2024, an estimated $1.87K.
  • &Partners first reported a position in Dogwood Therapeutics in Q2 2022 and held it in 10 quarters.
  • &Partners's Dogwood Therapeutics position peaked at $47K in Q2 2022.
  • 10 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q4 2024.

Based on &Partners's 13F filing for Q4 2024, filed 14 Feb 2025.